Latest From Novavax Inc.
In case you missed it: catch up with snippets from interviews recently published by In Vivo.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.
Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.
- Drug Delivery
- Specialty Pharmaceuticals
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Novavax Inc.
- Senior Management
Stanley C Erck, Pres. & CEO
John J Trizzino, SVP, CBO & CFO
Gregory M Glenn, MD, Pres., R&D
Russell P Wilson, SVP, Bus. Dev.
Louis F Fries, MD, CMO
- Contact Info
Phone: (240) 268-2000
20 Firstfield Rd.
Gaithersburg, MD 20878
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.